Condition

Adult Giant Cell Glioblastoma

ClinicalTrials.gov condition label

Clinical trials4

Recruiting0

Common interventions11

Lead sponsors shown3

Clinical trials

4 shown

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyNCT01806675 · 2013-03-04

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain MetastasesNCT02967380 · 2011-12-14

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsNCT01131234 · 2010-05-01

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionNCT00030498 · 2001-12-01

Common interventions

laboratory biomarker analysisOTHER2 18F-fludeoxyglucose (18F-FDG)DRUG1 18F-FPPRGD2DRUG1 Cediranib MaleateDRUG1 Dynamic Contrast-Enhanced Magnetic Resonance ImagingPROCEDURE1 erlotinib hydrochlorideDRUG1 Gadobenate DimeglumineDRUG1 GadobutrolDRUG1 Gadopentetate DimeglumineRADIATION1 Gamma-Secretase Inhibitor RO4929097DRUG1 Pharmacological StudyOTHER1

Leading sponsors

National Cancer Institute (NCI)2 Sanjiv Sam Gambhir1 University of Southern California1

Trial status mix

COMPLETED3

TERMINATED1

Phase mix

PHASE13

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.